15 results about "Dextran sodium sulfate" patented technology

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

This invention discloses the application of psoralen in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease.

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

The application discloses application of guaiacol in preparation of a drug for treating ulcerative colitis. Cell experiment results show that the guaiacol can enhance the ability of macrophages to remove apoptotic cells; animal experiment results show that the guaiacol can significantly relieve the disease of a dextran sodium sulfate (DSS)-induced ulcerative colitis mouse, and the specific performance is that the guaiacol can slow down the weight loss degree of the colitis mouse, effectively reduce the disease activity index (DAI) of the colitis mouse, significantly inhibit the shortening of the colon of the colitis mouse, the infiltration of inflammatory cells and the mucosal damage, obviously reduce the level of a pro-inflammatory factor in serum of the mouse, and increase the level of a pro-inflammatory repair factor. In conclusion, the guaiacol has definite curative effect on ulcerative colitis, has no obvious side effect, and has a good prospect of being developed into a drug for treating ulcerative colitis.

This invention discloses the application of psoralen chalcone in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease, non-alcoholic fatty liver disease, and osteoporosis.

The present invention relates to a composition for preventing, alleviating, or treating depression or anxiety disorder, the composition comprising a zeolite as an active ingredient, wherein the zeolite is excellent in increasing activity by alleviating depression or anxiety disorder in open-field tests and light-dark tests using a colitis animal model induced by dextran sulfate sodium salt (DSS), and is thus expected to be useful as a composition for preventing, alleviating, or treating depression or anxiety disorder.

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.

The application belongs to the field of biological medicine and microecological intervention technology, and relates to application of Bacillus coagulans T-21 in reducing ulcerative colitis combined with cognitive dysfunction. A dextran sodium sulfate (DSS) induced mouse ulcerative colitis combined with cognitive dysfunction model is established by taking a Bacillus coagulans T-21 strain as an active ingredient, and an intervention effect is evaluated. Results show that the Bacillus coagulans T-21 intervention can improve the cognitive related behavior performance and learning and memory ability of the model mice, thereby reducing ulcerative colitis related cognitive dysfunction. Meanwhile, the Bacillus coagulans T-21 intervention can increase the colon length, up-regulate the expression of tight junction proteins Occludin, Claudin-1 and Claudin-5 in colon tissue, improve the intestinal mucosal barrier damage, and down-regulate the expression levels of pro-inflammatory factors IL-1beta in colon tissue and IL-6 in hippocampus tissue, thereby reducing intestinal and central inflammatory reactions.

The present application relates to the technical field of prevention and treatment of intestinal inflammatory diseases, and in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the present application is an active heptapeptide derived from a natural protein, has a clear chemical structure and a reproducible preparation process. Research results show that the polypeptide can significantly improve the symptoms of ulcerative colitis induced by dextran sodium sulfate (DSS) in mice, including reducing body weight loss, reducing disease activity index (DAI), restoring colon length, improving colon tissue pathological damage and inhibiting inflammation-related signaling pathways, thereby verifying its improvement effect on intestinal inflammation. By preparing the polypeptide into a pharmaceutical composition, a comprehensive effect of prevention and treatment, inflammation improvement and barrier repair in parallel can be achieved, thereby providing a new strategy and material basis for the prevention and treatment of ulcerative colitis and other intestinal inflammatory diseases.

This invention belongs to the fields of marine product functional applications, functional foods, and biotechnology. It discloses an oyster oligopeptide for alleviating DSS-induced ulcerative colitis, its preparation method, and its uses. Using a DSS-induced damage model of normal human colonic epithelial cells as a guide, oyster meat was enzymatically hydrolyzed, defatted, and precipitated with alcohol to obtain purified oyster hydrolysate. Two oyster peptides were identified, screened using bioinformatics, and verified for synthesis. Their amino acid sequences are shown in SEQ ID NO. 1-2. The oyster oligopeptides exhibit strong antioxidant and anti-inflammatory activities, effectively alleviating DSS-induced NCM460 cell damage, with better effects than the positive control 5-aminosalicylic acid. They can be used to prepare drugs for alleviating ulcerative colitis, as well as foods and health products for adjuvant treatment of ulcerative colitis.

The present invention relates to a composition for preventing, alleviating, or treating intestinal fibrosis, the composition comprising zeolite as an active ingredient. The zeolite according to the present invention is highly effective in reducing the thickness of intestinal tissue and the accumulation of collagen in intestinal tissue and reducing the expression level of a gene related to fibrosis in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of an ɑ-smooth muscle actin (ɑ-SMA) protein in an intestinal fibrosis cell model induced by TGF-β.